{
    "clinical_study": {
        "@rank": "9844", 
        "arm_group": [
            {
                "arm_group_label": "Pegylated rhEPO", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe) of the test drug (Pegylated rhEPO)"
            }, 
            {
                "arm_group_label": "EPIAO\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, 3 case each dose group, of the comparator drug(EPIAO\u00ae) at day 1, 3, 5, 8, 10, 12."
            }
        ], 
        "brief_summary": {
            "textblock": "The object of this randomized, parallel, positive controlled study is to explore the\n      pharmacokinetics and pharmacodynamics profile of the test drug after single-dose\n      subcutaneous administration, compared to the comparator drug (EPIAO\u00ae) after multiple-dose\n      subcutaneous administration, by assessing plasma concentration of the drug and the\n      reticulocyte count, hemoglobin concentration and hematocrit following subcutaneous\n      administration, evaluate the security and tolerability of the test drug in healthy subjects,\n      and provide sufficient information for dose selection in the future phase II and III study."
        }, 
        "brief_title": "PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agree to all the purposes of the study by signing and dating the informed consent.\n\n          -  Male, aged between 18 and 40 years, age disparity of each group should less than 10\n             years.\n\n          -  Body weight \u2265 50kg, and body mass index (BMI) between 18 kg/m2 and 26kg/m2 at\n             screening.\n\n          -  Hemoglobin between 131g/L and 162g/L, hematocrit between 41% and 49%, and\n             reticulocyte between 0.5% and 2%.\n\n          -  Transferrin saturation and serum ferritin are in the normal range.\n\n          -  Physical condition: vital signs, physical examination and laboratory tests (\n             including routine blood, biochemical tests, coagulation indicators, serum folic acid,\n             vitamin B12, urine test, HBsAg, anti-HCV, anti-HIV, Immunoglobulin (IgA, IgM, IgG),\n             thyroid function (T3, T4, TSH), autoantibodies), chest-X-ray, 12-lead ECG should all\n             in normal range, or without significant clinically abnormal.\n\n        Exclusion Criteria:\n\n          -  Presence of organic disease in heart, liver, kidney, brain; or presence of\n             cardiovascular, pulmonary, gastrointestinal, urinary, neurological, endocrine,\n             immunity, genitourinary or other systems disease.\n\n          -  Subjects with familial genetic disease, mental illness, or physical disability.\n\n          -  History of drug allergy.\n\n          -  Orthostatic hypotension, systolic blood pressure <90mmHg.\n\n          -  Habitual medication, including Chinese herbal medicine.\n\n          -  Poor inclusion conditions (e.g. infirm).\n\n          -  Smoker (smoke everyday or more than 7 cigarettes per week)\uff0calcoholics (more than\n             40g/day, equivalent to 100ml/day of 50 degree of white spirit).\n\n          -  Participate in any other drug trials as the subjects within the previous 3 months.\n\n          -  As blood donated within the previous 3 months, or experienced massive blood loss due\n             to trauma or surgery.\n\n          -  Other conditions which in the opinion of the investigator precluding enrollment into\n             the study (e.g. poor compliance)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800305", 
            "org_study_id": "TB1209EPO"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pegylated rhEPO", 
                "intervention_name": "Pegylated rhEPO", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EPIAO\u00ae", 
                "intervention_name": "EPIAO\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "PK & PD study", 
            "rhEPO", 
            "Pegylated rhEPO", 
            "male healthy subject"
        ], 
        "lastchanged_date": "February 25, 2013", 
        "location": {
            "contact": {
                "email": "clinical@amoytop.com", 
                "last_name": "Wang Runhua, Ph.D", 
                "phone": "8605926889121"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "302 Military Hospital of China"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Positive-controlled, Single-dose, Dose-escalation Phase I Trial to Evaluate Safety & Tolerability, and Explore the Pharmacokinetics and Pharmacodynamics Profile of Pegylated rhEPO in Male Healthy Individual", 
        "overall_official": {
            "affiliation": "302 Military Hospital of China", 
            "last_name": "Wei Zhenman, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Time frame of day 12 for controlling drug: 0 hour before drug administration and 1, 3, 6,9, 12, 14, 16 hour after last dose administration.", 
                "measure": "Serum concentration of rhEPO", 
                "safety_issue": "No", 
                "time_frame": "0 hour before drug administration and 1, 3, 6, 9, 12, 14, 16, 24, 36, ,48, 72, 96, 120, 144, 168, 192, 216, 264, 288, 300, 312, 360, 408, 480, 648 hour after drug administration"
            }, 
            {
                "measure": "Plasma reticulocyte count", 
                "safety_issue": "Yes", 
                "time_frame": "0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216 264, 288, 312, 360, 408, 480, 648 hour after first drug administration. For controlling subjects, blood collection of 48, 96, 168,216, and 264 hour should before drug administration"
            }, 
            {
                "measure": "Plasma hemoglobin concentration", 
                "safety_issue": "Yes", 
                "time_frame": "0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216 264, 288, 312, 360, 408, 480, 648 hour after first drug administration. For controlling subjects, blood collection of 48, 96, 168,216, and 264 hour should before drug administration"
            }, 
            {
                "measure": "Plasma hematocrit", 
                "safety_issue": "Yes", 
                "time_frame": "0 hour before and 24, 48, 72, 96, 120, 144, 168, 192, 216 264, 288, 312, 360, 408, 480, 648 hour after first drug administration. For controlling subjects, blood collection of 48, 96, 168,216, and 264 hour should before drug administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800305"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Xiamen Amoytop Biotech Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xiamen Amoytop Biotech Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}